Pharmaceuticals
9 articles
Boehringer Ingelheim drug slashes liver and belly fat
In Phase 3 trials, Boehringer Ingelheim's experimental obesity drug, survodutide, helped recipients shed up to 17% of their body weight over 76 weeks, crucially preserving muscle mass.
Medicare offers $50 monthly GLP-1 access amid obesity drug competition
Starting July 1, 2026, eligible Medicare beneficiaries will pay just $50 a month for certain GLP-1 obesity drugs.
Lilly's oral obesity drug shows promising safety and tolerability
Lilly's experimental oral obesity drug, aleniglipron, helped patients lose up to 12.
AI Drug Development Surges: In Silico Trials Market Grows Dramatically
Biotech firm Insilico Medicine used artificial intelligence to discover a novel drug candidate for idiopathic pulmonary fibrosis (IPF) and advance it to Phase I clinical trials in under 30 months, acc
Legend Biotech stock surges on strong Q1 CAR T-cell therapy results
Legend Biotech's stock recently jumped 42% following new data, propelled by early clinical successes in difficult-to-treat cancers and robust sales of its existing CAR-T therapy, CARVYKTI, according t
Alnylam partners with Inceptive Nucleics for AI-driven RNAi therapeutics
Alnylam Pharmaceuticals, a leader in RNAi therapeutics, just committed $30 million upfront and up to $2 billion to Silicon Valley biotech startup Inceptive Nucleics.
Pfizer partners with Innovent Biologics for drug pipeline
Pfizer has committed up to $10.5 billion to a collaboration with Innovent Biologics in China to advance a pipeline of 12 novel therapies.
Trump Drug Pricing Deals Face Test as New Drugs Launch
The Medicare negotiated price for semaglutide, the active ingredient in blockbuster drugs like Ozempic, is $274 under the Inflation Reduction Act.
Merck Halts Parkinson's Drug Program After Phase 3 Setback
Merck's Parkinson's drug, preladenant, was discontinued in 2026 after Phase 3 trials showed it was no more effective than a placebo.